Nebulised Antibiotics for Inhalation Therapy

• US 20090025713A1
• Filed: 02/08/2007
• Published: 01/29/2009
• Est. Priority Date: 02/10/2006
• Status: Abandoned Application

• Current Assignee: PARI Pharma GmbH (PARI MEDICAL HOLDING GmbH)
• Original Assignee: PARI Pharma GmbH (PARI MEDICAL HOLDING GmbH)
• Inventors: Akkar, Aslihan, Keller, Manfred
• Application Number:
  US12/223,735
• Publication Number:
  US 20090025713A1
• Time in Patent Office: Days
• US Class Current: 128/200.160
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 47/6951 using cyclodextrin cyclodextrins used as simple excipients A61K47/40
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides pharmaceutical aerosols which are useful for the prevention or treatment of infectious diseases of the airways, such as the lungs, the bronchi, or the sinunasal cavities. The aerosols comprise an active agent selected from the group of quinolone antibiotics. Also disclosed are liquid and solid compositions suitable for being converted into the aerosols, and kits comprising such compositions.

Claims

1. A pharmaceutical aerosol for nasal, sinunasal or pulmonary administration comprising a dispersed liquid phase and a continuous gas phase, wherein the dispersed liquid phase

(a) essentially consists of aqueous droplets comprising an active compound selected from the group of quinolone antibiotics;

(b) has a mass median diameter from about 1.5 to about 6 μ

m; and

(c) has a droplet size distribution exhibiting a geometrical standard deviation from about 1.2 to about 3.0.

2. The aerosol of claim 1, wherein the active compound is selected from levofloxacin, gatifloxacin and moxifloxacin, including the pharmaceutically acceptable salts, solvates, isomers, conjugates, prodrugs and derivatives thereof.

3. The aerosol of claim 1, comprising at least one further active compound optionally selected from non-quinolone antibiotics, efflux pump inhibitors, compounds acting against bacterial biofilms, antifungals, antivirals, immunomodulators, lung surfactant, beta agonists, anticholinergics, steroids, mucolytics, heparinoids, anti-inflammatory and antiallergic drugs.

4. The aerosol of claim 1, being emitted from an aerosol generator at a rate of at least about 0.1 ml dispersed liquid phase per minute.

5. A liquid pharmaceutical composition for preparing the aerosol of claim 1, wherein a volume of not more than about 10 ml and more preferably less than about 5 ml of the composition comprises an effective dose of the active compound.

6. The composition of claim 5, having a dynamic viscosity in the range from about 0.8 to about 3 mPas.

7. The composition of claim 5, having a surface tension in the range from about 25 to 80 mN/m.

8. The composition of claim 5, comprising at least one excipient capable of affecting the local bioavailability, the release, and/or the local residence time of the active compound at the site of aerosol deposition.

9. The composition of claim 8, wherein the excipient capable of affecting the local bioavailability, the release, and/or the local residence time of the active compound is selected from the group consisting of complexing agents, polymers, and amphiphilic compounds.

10. The composition of claim 5, comprising at least one taste-modifying excipient, preferably selected from flavours, sweeteners, complexing agents and taste masking agents, such as a cyclodextrin, sugar, sugar alcohol, saccharin sodium, aspartame, or arginine.

11. The composition of claim 5, comprising at least one excipient selected from the group of di- or multivalent metal ions.

12. A solid pharmaceutical composition for preparing the liquid composition of claim 5, wherein the composition comprises an effective dose of the active compound, and wherein the solid composition is dissolvable or dispersible in an aqueous liquid solvent having a volume of not more than about 10 ml and more preferably less than 5 ml.

21. Use of the aerosol of claim 1 or of the liquid composition of claim 5 or of the kit of claim 13 for the preparation of a medicament for the prophylaxis or treatment of acute or chronic sinusitis or rhinosinusitis, bronchitis, pneumonia, chronic obstructive pulmonary disease, prophylaxis to prevent graft rejection after lung transplantation, parenchymatic and/or fibrotic diseases or disorders including cystic fibrosis with or without acute exacerbations, optionally due to Streptococcus pneumoniae, Haemophilus influenza or Moraxella catarrhalis;

acute bacterial exacerbations in chronic bronchitis or in chronic obstructive pulmonary disease, optionally due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Haemophilus parainfluenza or Moraxella catarrhalis;

nosocomial pneumonia, optionally due to Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Burkholderia cepacia, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenza or Streptococcus pneumoniae;

or community acquired pneumonia (CAP), or hospital acquired pneumonia (HAP), or ventilator associated pneumonia (VAP), optionally due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Haemophilus parainfluenza, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.

22. The use of claim 21, wherein the medicament is adapted for twice or once daily administration.

23. The use of claim 21, wherein the administration of a unit dose of the medicament takes not more than about 20 minutes and more preferably less than about 5 minutes.

13. A kit for the preparation and delivery of a pharmaceutical aerosol for nasal, sinunasal or pulmonary administration comprising a dispersed liquid phase and a continuous gas phase, wherein the dispersed liquid phase

(a) essentially consists of aqueous droplets comprising an active compound selected from the group of quinolone antibiotics;

(b) has a mass median diameter from about 1.5 to about 6 μ

m; and

(c) has a droplet size distribution exhibiting a geometrical standard deviation from about 1.2 to about 3.0,

wherein the kit comprises a nebuliser and an aqueous liquid composition, said composition comprising an effective dose of the active compound within a volume of not more than about 10 ml and more preferably less than 5 ml.

14. The kit of claim 13, wherein the nebuliser is selected from the group consisting of jet nebulisers, ultrasonic nebulisers, jet collision nebulisers, electrohydrodynamic nebulisers, capillary force nebulisers, perforated membrane nebulisers and perforated vibrating membrane nebulisers.

15. The kit of claim 13, wherein the nebuliser is adapted to be capable of aerosolising the liquid composition at a rate of at least about 0.1 ml/min.

16. The kit of claim 13, wherein the nebuliser is adapted to be capable of aerosolising a volume of the liquid composition comprising an effective dose of the active compound within not more than about 20 minutes and more preferably less than about 5 minutes.

17. The kit of claim 13, wherein the nebuliser is adapted to be capable of emitting at least about 50 wt.-% of the aqueous liquid composition as aerosol.

18. The kit of claim 13, wherein at least about 40 wt.-% of the loaded dose is comprised of droplets having a diameter of not more than about 5 μ

m.

19. A method of preparing and delivering an aerosol to a person in need of nasal, sinunasal or pulmonary antibiotic treatment or prophylaxis, said method comprising the steps of:

(a) providing a liquid pharmaceutical composition comprising an effective dose of an active compound selected from the group of quinolone antibiotics in a volume of not more than about 10 ml and more preferably less than 5 ml;

(b) providing a nebuliser capable of aerosolising said liquid pharmaceutical composition at a total output rate of at least 0.1 ml/min, the nebuliser further being adapted to emit an aerosol comprising a dispersed phase having a mass median diameter from about 1.5 to about 6 μ

m and a geometrical standard deviation from about 1.2 to about 3; and

(c) operating the nebuliser to aerosolise the liquid composition.

20. The method of claim 19, wherein step (c) is conducted to last not more than about 20 minutes and more preferably less than about 5 minutes.

24. The use of a polymeric compound as excipient in a pharmaceutical composition for the preparation of an aerosol, wherein the composition comprises an active compound selected from the group of quinolone antibiotics.

25. The use of claim 24, wherein the polymeric compound is selected from chitosan, cellulose derivatives, dextran, and cyclodextrins.